DelveInsight Blogs Sitemap

All Posts in this category
S.No. Product Name Actions
1 Systemic Lupus Erythematosus Treatment Market: How the Leading Companies are Countering the Rising Prevalence? Visit Post
2 AstraZeneca's Ultomiris; HebaBiz's Siroquine; Pfizer's XELJANZ; Bristol Myers Squibb's Opdivo; and Masimo's PVi Visit Post
3 LQTT secures $19M; Nanox acquires Zebra Medical Vision; Takeda leads IBD drug; Visus raises $20M Visit Post
4 Peanut Allergy Market Outlook: The Market Size Growth Sees Major Thrusts Visit Post
5 Leading Autoimmune Diseases to Undergo Robust Improvement in Treatment by Major Pharma Companies Visit Post
6 Aelis Farma pockets $30M; Alcyone unveils $23M for AAV gene therapies; Progentec and GSK collaborate; Kozin bags $60M Visit Post
7 Essential Demands Impinge the Evolving Adult-onset Still’s Disease Treatment Market Visit Post
8 Is Antibody-mediated Rejection a Roadblock to Organ Transplantation? Visit Post
9 Lilly ink deal with MiNA; Appia Bio aims for CAR-T with $52M raise; Nuvalent raises $135M; Orchard gene therapy benefits kids Visit Post
10 Arch Oncology scores $105M; Abbott’s new coronary imaging platform; Lilly scraps IL-23 psoriasis program; Biogen offer access to experimental ALS med Visit Post
11 Kinase Inhibitors: Challenging the established Biologics as the new standard of care in autoimmune diseases? Visit Post
12 A New Addition to Existing Chimeric Antigen Receptor Therapies –Potential for a Game Changer in Blood Cancers Visit Post
13 Hemophilia B Market: How Pipeline Therapies are Transforming the Treatment Hemisphere? Visit Post
14 A Royal Disease: Hemophilia Visit Post
15 Beam makes USD 120M bet; GRAIL and Quest announce the collaboration; Brain organoids mimic infant’s brains; Improvement in T cells to kill cancer Visit Post
16 Verily - Janssen collaboration; Enhancing the response in pancreatic cancer; Avrobio gene therapy eradicates toxic substrate; Gut microbiome responsible for Multiple Sclerosis Visit Post
17 Plaque psoriasis drug outshines in phase III trial; Immunovant announces pause in trial of IMVT-1401; Prothena brings AL amyloidosis drug back; Canon Medical expands its MRI AI programs Visit Post
18 Horizon, Viela Deal; Concert Schizo Drug Flop; Gilead Deals with Arcus and Gritstone Visit Post
19 A Bleak Pipeline and Lack of Approved Treatment Clouds the Hemophagocytic Lymphohistiocytosis Market Size Growth Visit Post
20 Thrombocytopenia Drugs Market: What Newer Agents Are Expected To Enter The Market? Visit Post
21 Gilead and Vir collaborate; Tessera scores $230M; Teladoc & Dexcom bring CGM Tech; Verve unveils lead candidate Visit Post
22 Increasing Prevalence and Upcoming Novel Therapeutic Approaches: What is Shaping the Hepatitis D Market Outlook? Visit Post
23 Search for the Cure Continues in the Chronic Hepatitis B Treatment Market Visit Post
24 Rheumatoid Arthritis: Causes, Risk Factors, Treatment Approaches and Market Landscape Visit Post
25 Fierce Competition Lies Ahead for Pipeline Therapies in the Rheumatoid Arthritis Market Visit Post
26 The Present Rheumatoid Arthritis Treatment Market Offers a Mix-and-Match Approach Visit Post
27 Brain's immune cells research update; Moderna's COVID-19 vaccine; Pfizer funnels $200 M into CStone; Myovant's relugolix falls short in metastatic prostate cancer; Alnylam's lumasiran phase 3 result Visit Post
28 The State of Alternative Medicine In The Healthcare Visit Post
29 Healthcare Delivery System: What lies in the future? Visit Post
30 FDA rejects BioMarin's Valoctocogene Roxaparvovec; J&J inks $6.5B deal; Alzheon bags $47M; Research updates on diabetes Visit Post
31 Sanofi acquires Principia; FDA's Nod to Roche's Enspryng; BMS, Dragonfly's Licensing Deal Visit Post
32 Celiac Disease: The Hidden Epidemic of Gluten Sensitivity Visit Post
33 Boehringer Ingelheim; Roche demonstrated new analyses of their drugs in patients with ILDs during the American Thoracic Society (ATS) Virtual conference Visit Post
34 Zydus starts Phase II COVID-19 vaccine trial; Taysha raises $95M; FDA declines DBV's peanut allergy patch; Combating COVID-19 with decoy target Visit Post
35 Kiadis inks license deal with Sanofi; Gilead Ends Hep B Collaboration; Merck & Foghorn inks $425M deal; Tregs research updates Visit Post
36 HCQ/ CQ failure; AZ/ Catalent’s deal; Sinovac’s CoronaVac and Lilly’s Olumiant trial results Visit Post
37 R&D and Upcoming therapies Paving the Way for a Potential and Better Cure for Immune Thrombocytopenia Visit Post
38 In the fight against COVID-19 – Lilly with Olumiant, Gilead with remdesivir, Rutgers with testing kit Visit Post
39 Bioelectronic Medicine: Applications and Future Prospects Visit Post
40 Moderna’s COVID-19 vaccine; AcelRx buys TetraPhase; Breakthrough designation to Baricitinib Visit Post
41 JNJ-6372 nabs FDA nods, Solid tumors treatment, Kevzara for COVID-19 Visit Post
42 First-ever Peanut allergy treatment; Dinutuximab misses primary endpoint; Insmed's shares Soares Visit Post
43 Thyroid awareness month Visit Post
44 Thyroid eye disease market: New therapies enter the TED market Visit Post
45 Tepezza receives approval; a new way to treat Alzheimer’s Visit Post
46 Imfinzi combo gets ODD; Mayzent gets EU nod; Positive results of VP-102 Visit Post
47 Thumbs down to NKTR-181, Lilly expands its insulin armamentarium Visit Post
48 Eli Lilly to acquire Dermira, Boehringer buys Enleofen’s IL-11 platform, Biogen acquires Pfizer’s Alzheimer’s drug Visit Post
49 Egg Allergy Market: Second most common food allergy but no approved therapy Visit Post
50 Allergic rhinitis market: How common is Hay fever? Visit Post
51 Global Allergic disease market Visit Post
52 Omega’s sixth funding round; Correvio’s drug failure; and BIMA acquisition Visit Post
53 Acquisition of ArQule; Synthorx; and Zentalis nabs a raise Visit Post
54 Cumberland’s methotrexate product gets approval in the US; Baker Brothers purchases stake in Kodiak’s KSI-301; Sanofi offloads Seprafilm unit to Baxter Visit Post
55 Novartis buys Medicines Co. for USD 9.7 Billion Visit Post
56 The long journey of Biosimilars: Is it an emerging opportunity? Visit Post
57 AbbVie Sells bonds to Fund Allergan takeover Visit Post
58 AZ sells EU rights for Schizophrenia to Cheplapharm; Astellas, Pandion unite to extract the potential of immunomodulation; Pear therapeutics on a journey to develop digital GI treatments with Ironwood Visit Post
59 Incyte Corporation submits positive results of trials for its drug Ruxolitinib in GvHD Visit Post
60 AngioDynamics acquires Eximo; MiroBio raises USD 33 M; Janssen submits sBLA for Stelara Visit Post
61 FDA is reviewing a dangerous way to treat Peanut Allergy Visit Post
62 Roche’s Gazyva receives FDA Breakthrough designation for Lupus nephritis Visit Post
63 Fujifilm acquires global rights to Cynata's novel therapy for GvHD; Themis raises EURO 40 million for Chikungunya vaccine; Bayer to license One Drop's digital diabetes platform Visit Post
64 Helsinn out licenses Pracinostat in South America Visit Post
65 Psoriasis Pipeline: Upcoming Psoriasis Treatments Visit Post
66 Psoriasis Therapy Market Size  Visit Post
67 Juvenile Idiopathic Arthritis Therapy Market Visit Post
68 Juvenile Idiopathic Arthritis Awareness Month Visit Post
69 PureHealth acquires LYT-100; Sosei raises USD 2.5 M Visit Post
70 Juvenile Idiopathic Arthritis Etiology and Epidemiology Visit Post
71 Osivax raises USD 9M; Smyraf launched; Revolution secures USD 100M Visit Post
72 Myasthenia gravis Market Outlook Visit Post
73 Myasthenia Gravis Awareness Month Visit Post
74 Recent Market Reports Visit Post
75 GSK to spend $100M; Lilly sell; Sherlock Bio raises $31M; Deerfield, UIC to foster research Visit Post
76 World Immunization Week Visit Post
77 Narcolepsy now a confirmed Autoimmune Disorder Visit Post
78 Notizia Visit Post
79 Notizia Visit Post
80 Notizia Visit Post
81 Notizia Visit Post
82 Orchard files for IPO; J&J puts money on RNA interference; Rgenix receives $40M; GSK gives a helping hand Visit Post
83 Notizia Visit Post
84 Ceribell raises $35M; Lyra reels $29.5M; Minoryx raises Euro21M; Alexion acquired Syntimmune Visit Post
85 Outset Medical captures; Wright Medical Group to takeover Cartiva; Y-mAbs Therapeutics prepares for IPO; Biotech boom remunerates analysts Visit Post
86 AZ dragout Entasis; Sierra remunerates Gilead; Principia raises; Harbour BioMed and Kelun pen deal Visit Post
87 Fatty Acid Amide Hydrolase (FAAH) Inhibitor – an enzyme with novel therapeutic potential Visit Post
88 Celiac vaccine trial; New discovery in Nicotine; Nabriva lines up FDA filing; Rare Disease drug development accelerating Visit Post
89 Business Cocktail Visit Post
90 Business Cocktail Visit Post
91 Celiac Disease – Intestinal damage of Gluten Visit Post
92 Involvement of B cells in the pathogenesis of primary Sjögren syndrome (pSS) Visit Post
93 Notizia Visit Post
94 NOTIZIA Visit Post
95 Gaucher Disease: “Rare Disorder with High Unmet Needs” Visit Post
96 December 7 Business Cocktail Visit Post
97 Biohaven’s trial ; GSK integrates; FDA Approval; Phase III trial Visit Post
98 Celiac Disease (CD) – Upcoming therapies to break the stagnancy Visit Post
99 EMA to relocate to Amsterdam; Roche’s prospects; Amgen’s Humira Biosimilar delayed; Purdue’s opioid lawsuit Visit Post
100 Teva sells generics; Valeant trades; Roche's Genentech; J&J's next potential frontier Visit Post
101 Therapeutics and Celgene to develop therapies; Takeda’s expansion; J&J hopes to limit; Tech Prize for genome sequencing; Endocyte’s late-stage prostate cancer deal Visit Post
102 Alzeimer’s drug; Guardant Health receives approval; First Patient Dosed in Phase 1 Clinical Trial; Sunny Pharmtech and Vitruvias Therapeutics Receive FDA Approval Visit Post
103 Business Cocktail Visit Post
104 Idera’s Phase I Data; DelMar Initiates Trial; Novartis’ study; Humira gets EC approval Visit Post
105 Can-Fite Receives Payment; Leafbuyer Technologies and Denver Post’s Cannabist; EPX-300 & JOTROL received Designation; New treatment Approved for adults Visit Post
106 Bristol-Myers Squibb to nix; Pfizer commits $100M; Merck and GSK production issues; Shire unloads plant Visit Post
107 Allergan sell; AZ, Merck team up; Roche’s MS drug; Chinese API maker receives a warning letter Visit Post
108 Remicade’s launch; Endo cuts jobs; Analysts downgrade Pfizer; Corning $500M glass project Visit Post
109 Gilead faces lawsuit; Herceptin stalled; Lilly revs up, Abemaciclib gets nod; Key Humira patent gets struck down Visit Post
110 J&J nabs; Clovis plots Rubraca; Novartis scores EU approval; Seattle Genetics stops trials Visit Post
111 Tesaro’s Zejula; Mylan on EpiPen; Ohio sues drugmakers; ATUM, Horizon Discovery Announce deal Visit Post
112 Roche, Boehringer tout; Pfizer, Bristol-Myers got sued; FDA commissioner unveils; EpicGenetics expands Visit Post
113 Merck's Remicade; Sanofi, Regeneron set Kevzara; Novartis to sever; Teva puts women's health Visit Post
114 AZ’s benralizumab; Sanofi, Regeneron set; Nordisk preps; European countries offer Visit Post
115 Humira’s patent; Teva laying off; GSK aims; Thermo acquires Patheon; J& J's Invokana Visit Post
116 Merck sells biosimilars; AbbVie’s PARP; Pharma heads; Biogen looks to M&A Visit Post
117 Samsung biosim nod sets; Lilly's med hits; BioMarin sees pricing; Spinraza scores; Klick creates Visit Post
118 Novartis gets CAR-T drug; Shire aims to block; Xeljanz stands; Payer snubs; Lawmakers pass a bill Visit Post
119 Valeant's asset-sale; Sanofi coughs up $19.8M; Sanofi's Genzyme; India's Alkem; GSK’s inhalers Visit Post
120 Tesaro puts AstraZeneca; XELJANZ® receives; Innovus nabs; Alexion brings Visit Post
121 Letter for AstraZeneca; Patheon on API plant; Sanofi, Regeneron’s Dupixent; Cerulean Pharma and Daré Bioscience enter into deal; Lilly on price hikes Visit Post
122 Chronic Obstructive Pulmonary Disorder Visit Post
123 AstraZeneca announces; Trivitron launches; BrainStorm Cell Therapeutics validates Visit Post
124 Payers block EpiPen; Allergan charged; AbbVie's Humira; Baxter paying $18M Visit Post
125 Astellas ditches UMN Pharma; J&J, Actelion land on a price; Bayer’s pledge; Biogen to fork over $1.25B-plus Visit Post
126 Biosimilars: A benchmark in Pharmaceutical Business Visit Post
127 Systemic Lupus Erythematosus: An autoimmune disease Visit Post
128 Chronic Obstructive Pulmonary Disease (COPD): Scenario Visit Post
129 Pfizer uses; FDA approves; EMA approves; Mylan launches Visit Post
130 Sjogren's syndrome- Autoimmune Attack on Salivary and Tear Glands Visit Post
131 On World AIDS Day... Visit Post
132 Novartis Buys; FDA approves; Mayne Pharma Launches; Oxford Genetics Receives Grant Visit Post
133 Novartis eyes; Pfizer considers cashing; Mylan pushes to seal $465M; Valeant with Takeda for deal Visit Post
134 Collaborate for TYG Oncology; GE Healthcare and Valneva collaboration; UPS to Acquire Marken Visit Post
135 Biosimilar Market in India Visit Post
136 Boston Biomedical starts phase III; Martindale receives approval; Merck snagged yes; Nanotechnology to improve HIV Visit Post
137 Sun Pharma & ICGEB announce collaboration; Boehringer Ingelheim and Lupin Sign deal; Daiichi Sankyo Announces; Catalent Pharma Solutions partners with Samsung Bioepis; Celltrion Healthcare and Teva enters into exclusive business collaboration agreement Visit Post
138 Taltz (Ixekizumab) in Treatment of Plaque psoriasis Visit Post
139 FDA grants approval; Sanaria receives fast-track designation; Sanofi and Regeneron’s next blockbuster; Allele receives NIH grant Visit Post
140 Graft vs Host Disease (GVHD): Treatment approaches and Trends Visit Post
141 Sun Pharma forms partnership; Pfizer and DCRI collaborate; Avara Acquires AZ; ASLAN Pharmaceutical’s Collaboration; Amgen and Servier partnership Visit Post
142 BI & Duke Clinical Research Institute have expansion; BioInvent Inks Mfg. Pact; Elite Pharma, SunGen Pharma in Development & License Deal; Boehringer and Saniona Develop new Compounds; BioLineRx and I-Bridge Capital Establish; Alliance between Harvard and Tata Companies; Innovative Targeting Solutions and Johnson & Johnson Innovation collaborate Visit Post
143 The Road Less Travelled: EpiPen's Pricing Policy Visit Post
144 Rheumatoid Arthritis Market, Epidemiology and Market Forecast-2020 Visit Post
145 PD-1 and PD-L 1 inhibitors – Competitive Landscape, Pipeline and Market Analysis, 2016 Visit Post
146 LAG-3 Antagonists, TIM-3 Antagonists; OX40 Agonists- Pipeline Insights, 2016 - A DelveInsight Report Visit Post
147 Systemic Juvenile Idiopathic Arthritis -Pipeline Insights, 2015 Visit Post
148 DelveInsight launches Indication Active Pharmaceutical Ingredient (API) Reports Visit Post
149 DelveInsight’s Immunology based Gene Therapy Reports Visit Post
150 Rheumatoid Arthritis Market Analysis Visit Post
151 Celecoxib first Generic Approval to Teva and Mylan from FDA Visit Post